# Phase 3 Study to Evaluate the Efficacy and Safety of the DW0929 in Patients With Primary Hypercholesterolemia

> **NCT02390375** · PHASE3 · COMPLETED · sponsor: **Daewon Pharmaceutical Co., Ltd.** · enrollment: 348 (actual)

## Conditions studied

- Hypercholesterolemia

## Interventions

- **DRUG:** DW-0929
- **DRUG:** DW-0929
- **DRUG:** DW-0929
- **DRUG:** Rosuvastatin
- **DRUG:** Rosuvastatin
- **DRUG:** Rosuvastatin

## Key facts

- **NCT ID:** NCT02390375
- **Lead sponsor:** Daewon Pharmaceutical Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-11
- **Primary completion:** 2016-04
- **Final completion:** 2016-05
- **Target enrollment:** 348 (ACTUAL)
- **Last updated:** 2016-10-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02390375

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02390375, "Phase 3 Study to Evaluate the Efficacy and Safety of the DW0929 in Patients With Primary Hypercholesterolemia". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02390375. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*